









市場行情
/
股票
/
nasdaq-celc
/

Celcuity Inc

CELC

99.740USD

-0.180-0.18%

收盤 12/31, 16:00（美東）報價延遲15分鐘

4.32B總市值

虧損本益比TTM



Celcuity Inc

99.740

-0.180-0.18%

概覽公司財務分析

概覽

公司

財務

分析

關於 Celcuity Inc 公司

Celcuity Inc. is a clinical-stage biotechnology company, which develops targeted therapies for the treatment of multiple solid tumor indications. Its lead therapeutic candidate is gedatolisib, a potent, small-molecule reversible inhibitor that selectively targets all Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2. Its development programs for gedatolisib focus on the treatment of patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), or HR+/HER2-, advanced or metastatic breast cancer and patients with metastatic castration resistant prostate cancer. A Phase III clinical trial of VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast has commenced. Its CELsignia companion diagnostic platform is able to analyze live patient tumor cells.

Celcuity Inc簡介



公司代碼CELC

公司名稱Celcuity Inc

上市日期Sep 20, 2017

CEOSullivan (Brian F)

員工數量87

證券類型Ordinary Share

年結日Sep 20

公司地址16305 36th Ave N Ste 100

城市MINNEAPOLIS

上市交易所NASDAQ OMX - NASDAQ BASIC

國家United States of America

郵編55446-4285

電話17633920767

網址https://www.celcuity.com/

公司代碼CELC

上市日期Sep 20, 2017

CEOSullivan (Brian F)

Celcuity Inc公司高管



名稱

名稱/職務

職務

持股

持股變動

Mr. Brian F. Sullivan

Chairman of the Board, Chief Executive Officer, Co-Founder

3.12M

+3.18%

Mr. Richard J. Nigon

Independent Director

109.01K

+7.83%

Ms. Vicky Hahne, CPA

Chief Financial Officer

18.86K

+1.63%

Dr. Richard E. Buller, M.D., Ph.D.

Independent Director

7.71K

-0.64%

Dr. Polly A. Murphy, DVM, Ph.D.

Independent Director

5.00K

Dr. Lance G. Laing, Ph.D.

Co-Founder, Chief Science Officer, Vice President, Secretary, Director

Mr. David F. Dalvey

Independent Director

Dr. Charlotte Moser, M.D., Ph.D.

Chief Medical Officer

Dr. Leo T. Furcht, M.D.

Independent Director

名稱

名稱/職務

職務

持股

持股變動

Mr. Brian F. Sullivan

Chairman of the Board, Chief Executive Officer, Co-Founder

3.12M

+3.18%

Mr. Richard J. Nigon

Independent Director

109.01K

+7.83%

Ms. Vicky Hahne, CPA

Chief Financial Officer

18.86K

+1.63%

Dr. Richard E. Buller, M.D., Ph.D.

Independent Director

7.71K

-0.64%

Dr. Polly A. Murphy, DVM, Ph.D.

Independent Director

5.00K

Dr. Lance G. Laing, Ph.D.

Co-Founder, Chief Science Officer, Vice President, Secretary, Director

收入明細

由於公司未披露，未能獲取相關數據

由於公司未披露，未能獲取相關數據

業務

地區

由於公司未披露，未能獲取相關數據

股東統計

更新時間: 12月7日週日

持股股東

股東類型

持股股東

佔比

Baker Bros. Advisors LP

17.11%

Sullivan (Brian F)

6.75%

Perceptive Advisors LLC

6.39%

New Enterprise Associates (NEA)

4.63%

The Vanguard Group, Inc.

4.45%

其他

60.67%

持股股東

佔比

Baker Bros. Advisors LP

17.11%

Sullivan (Brian F)

6.75%

Perceptive Advisors LLC

6.39%

New Enterprise Associates (NEA)

4.63%

The Vanguard Group, Inc.

4.45%

其他

60.67%

股東類型

持股股東

佔比

Hedge Fund

34.24%

Investment Advisor

23.81%

Individual Investor

10.32%

Investment Advisor/Hedge Fund

9.98%

Private Equity

6.79%

Research Firm

5.83%

Venture Capital

5.21%

Corporation

0.76%

Pension Fund

0.18%

其他

2.89%

機構持股



更新時間: 12月8日週一

報告期間

機構數

持股數

持股佔比

持股變動

2025Q4

306

39.76M

85.92%

-806.98K

2025Q3

298

39.50M

98.78%

+3.79M

2025Q2

215

31.87M

95.31%

+797.76K

2025Q1

207

31.06M

92.46%

-3.93M

2024Q4

197

30.50M

91.70%

-18.57K

2024Q3

181

30.14M

86.73%

+764.96K

2024Q2

164

29.36M

68.66%

+7.16M

2024Q1

155

22.20M

60.61%

+3.55M

2023Q4

137

16.81M

74.10%

+667.49K

2023Q3

139

16.14M

75.21%

+1.37M

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

Baker Bros. Advisors LP

7.92M

17.11%

+170.10K

+2.20%

Sep 30, 2025

Sullivan (Brian F)

3.12M

6.75%

+96.19K

+3.18%

Sep 30, 2025

Perceptive Advisors LLC

2.96M

6.39%

+285.72K

+10.70%

Sep 30, 2025

New Enterprise Associates (NEA)

2.14M

4.63%

Sep 30, 2025

The Vanguard Group, Inc.

2.06M

4.45%

+391.26K

+23.46%

Sep 30, 2025

BlackRock Institutional Trust Company, N.A.

2.04M

4.42%

+174.80K

+9.35%

Sep 30, 2025

Morgan Stanley & Co. LLC

1.27M

2.74%

+743.94K

+142.39%

Sep 30, 2025

Laing (Lance G Ph.D.)

1.25M

2.7%

Sep 30, 2025

Soleus Capital Management, L.P.

1.18M

2.55%

-1.83M

-60.86%

Sep 30, 2025

Tang Capital Management, LLC

1.15M

2.49%

+1.15M

Sep 30, 2025

持股ETF



更新時間: 12月6日週六

機構名稱

佔比

iShares Genomics Immunology and Healthcare ETF

5.06%

Virtus LifeSci Biotech Clinical Trials ETF

4.16%

Tema Oncology ETF

3.44%

Invesco Dorsey Wright Healthcare Momentum ETF

3.35%

ALPS Medical Breakthroughs ETF

1.34%

Invesco Dorsey Wright SmallCap Momentum ETF

0.89%

iShares Micro-Cap ETF

0.44%

VictoryShares US Small Mid Cap Value Momentum ETF

0.26%

Vanguard US Momentum Factor ETF

0.16%

State Street SPDR S&P Biotech ETF

0.15%

iShares Genomics Immunology and Healthcare ETF

佔比5.06%

Virtus LifeSci Biotech Clinical Trials ETF

佔比4.16%

Tema Oncology ETF

佔比3.44%

Invesco Dorsey Wright Healthcare Momentum ETF

佔比3.35%

ALPS Medical Breakthroughs ETF

佔比1.34%

Invesco Dorsey Wright SmallCap Momentum ETF

佔比0.89%

iShares Micro-Cap ETF

佔比0.44%

VictoryShares US Small Mid Cap Value Momentum ETF

佔比0.26%

Vanguard US Momentum Factor ETF

佔比0.16%

State Street SPDR S&P Biotech ETF

佔比0.15%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

類型

比率

暫無數據

公告日期

類型

比率

暫無數據

常見問題

Celcuity Inc的前五大股東是誰？



Celcuity Inc的前五大股東如下：
Baker Bros. Advisors LP
持有股份：7.92M
佔總股份比例：17.11%。
Sullivan (Brian F)
持有股份：3.12M
佔總股份比例：6.75%。
Perceptive Advisors LLC
持有股份：2.96M
佔總股份比例：6.39%。
New Enterprise Associates (NEA)
持有股份：2.14M
佔總股份比例：4.63%。
The Vanguard Group, Inc.
持有股份：2.06M
佔總股份比例：4.45%。